A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease
Status:
Completed
Trial end date:
2020-06-02
Target enrollment:
Participant gender:
Summary
This trial aims to investigate the safety, tolerability and clinical activity of humanised
antibody GSK1070806 delivered via intravenous infusion in the treatment of patients with
moderate-to-severe Crohn's disease. 30-36 patients will be enrolled into the trial, with two
thirds of the patients receiving active drug and one third receiving placebo. After 30
patients have been recruited into the study the sample size will be reassessed and up to an
additional 6 patients could be recruited (i.e. up to 36 patients).